Being Limitless in our approach to reach twice as many patients, twice as fast, to deliver twice the growth. Leading Novartis’ Innovative Medicines in the GCC, with over 500 extremely talented professionals in a highly diverse region, our aim is to positively impact lives by accelerating access and reach in delivering quality healthcare to twice as many patients twice as fast.
Rethinking strategies is crucial as we look at new approaches to access treatment and create greater impact for our patients, customers, and healthcare systems. In the GCC, we continue to focus on digitalization, which is key to a transforming business model, and answering customer needs through next generation engagement.
It is Novartis' commitment to develop new capabilities and evolve our ways of working to continue to drive toward a more patient centric and agile model of business.
In my position as Head of the GCC, I spearhead engagement with partners across these regions to identify opportunities to deliver faster innovative treatments.
Remaining steadfast in our mission, we continue to reimagine medicine to improve and extend people’s lives.
About the speaker
- Name: Georg Schroeckenfuchs
- Company: Novartis
- Designation: Head Gulf & Saudi Country Group IM
- Regional Headquarters : U.A.E.
- Sector: Pharmaceuticals
Georg Schroeckenfuchs heads Switzerland-based Novartis’s regional hub in Dubai, which manages a $1.3 billion portfolio across 19 countries and employs more than 2,500 people. Novartis uses scientific innovations and technology to advance the pharma industry. Schroeckenfuchs joined Novartis in 2001 and has held roles as CPO Head and Country President in Italy, Greece, Poland, and the Baltic Countries.
